Eli Lilly and Company (NEO:LLY)

Canada · Delayed Price · Currency is CAD

36.65

-0.17 (-0.46%)

Dec 5, 2025, 3:18 PM EST

20.72% (1Y)

Market Cap	1.25T
Revenue (ttm)	82.77B
Net Income (ttm)	25.65B
Shares Out	n/a
EPS (ttm)	28.47
PE Ratio	48.90
Forward PE	32.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,222
Average Volume	62,882
Open	36.92
Previous Close	36.82
Day's Range	36.62 - 37.31
52-Week Range	22.85 - 40.49
Beta	0.39
RSI	52.90
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 1876

Employees 47,000

Stock Exchange Cboe Canada

Ticker Symbol LLY

Full Company Profile

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD Financial Statements

News

There is no news available yet.